Taube T, Elomaa I, Blomqvist C, Beneton M N, Kanis J A
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Eur J Cancer. 1993;29A(12):1677-81. doi: 10.1016/0959-8049(93)90103-m.
We studied the effects of long-term treatment with clodronate, calcitonin or placebo on bone in 36 normocalcaemic women with osteolytic metastases due to breast cancer. Clodronate (1.6 g daily given to 12 patients) induced a significant decrease in osteoclast surface and osteoclast number, and a significant fall in serum calcium and urinary excretion of calcium and hydroxyproline, an effect not noted after treatment with calcitonin (100 U in 12 patients) or in 12 placebo-treated patients. Treatment with clodronate did not abnormally suppress bone turnover nor impair mineralisation, as measured by bone formation and mineral apposition rates.
我们研究了氯膦酸盐、降钙素或安慰剂长期治疗对36名因乳腺癌发生溶骨性转移的血钙正常女性骨骼的影响。氯膦酸盐（12名患者每日服用1.6克）使破骨细胞表面和破骨细胞数量显著减少，血清钙以及钙和羟脯氨酸的尿排泄量显著下降，而降钙素（12名患者服用100单位）治疗后或12名接受安慰剂治疗的患者中未观察到这种效果。通过骨形成和矿物质沉积率测量发现，氯膦酸盐治疗并未异常抑制骨转换，也未损害矿化作用。
